September 2026 Research Update

This month added clearer long-term evidence that allogeneic hematopoietic stem cell transplantation (HSCT, a donor stem cell transplant) can slow down late-onset metachromatic leukodystrophy (MLD), but results depend strongly on timing. Across groups, HSCT was linked with a delay in reaching advanced disease and with better quality-of-life and daily functioning compared with being untreated, and the strongest pattern was seen when HSCT happened before symptoms began. The study also showed that HSCT does not always stop symptoms from progressing, even when used early. [1]

In this European registry study following some people for as long as 25 years, advanced disease was reported less often in the pre-symptomatic HSCT group than in symptomatic HSCT-treated or untreated patients. The study also reported better patient-reported quality-of-life and daily-life functioning measures with HSCT across disease stages, with the biggest benefits in the pre-symptomatic group. This helps clarify that the window before clear symptoms may be especially important for preserving day-to-day abilities, while still recognizing that outcomes vary by person. [1]

For families affected by late-juvenile or adult (late-onset) MLD, these results mainly add longer-term expectations about what HSCT might and might not accomplish. The evidence points to a meaningful difference between treatment before symptoms and treatment after symptoms start, especially for maintaining function and quality-of-life, but it also shows HSCT is not a guarantee against progression. This may matter most when families are trying to understand prognosis and the potential impact of early identification, but it does not by itself answer which individuals should receive HSCT or when. [1]

This month reinforced that MLD can affect parts of the body outside the brain and nerves, and that these issues can be clinically important. A systematic review found gallbladder abnormalities were reported in a large share of people with MLD, including some before neurologic diagnosis and after disease-modifying treatment, meaning gallbladder changes are not limited to late-stage disease. A separate hospital-database study across leukodystrophies found that when children are sick enough to be hospitalized, deaths were more common in situations involving intensive care, infections, and major supportive therapies, and MLD accounted for a substantial portion of these inpatient deaths. [2] [3]

In the gallbladder review, 111 of 128 individuals with reported gallbladder status had abnormalities, most commonly wall changes or inflammation, gallbladder growths (polyps or papillomatous lesions), and sludge or stones. The review also noted severe complications were reported in some cases, and that available data did not support the idea that gallbladder involvement happens only in late-infantile or neurologically advanced MLD. This makes the overall picture clearer: gallbladder issues can appear across the MLD spectrum, including in people being evaluated for gene therapy. [2]

In the pediatric inpatient study (covering many leukodystrophy types, not only MLD), inpatient mortality was 5.2%, and MLD represented 28% of the inpatient deaths recorded. Deaths occurred more often alongside long hospital stays, ICU care, infections, mechanical ventilation, and total parenteral nutrition, and mortality appeared lower at hospitals that see more leukodystrophy patients. For MLD families, this mainly clarifies what often surrounds severe hospital illness rather than giving a day-to-day forecast for someone living at home. [3]

For patients and caregivers, these studies broaden what is understood about MLD-related health monitoring and risks. The gallbladder review suggests gallbladder changes are common in published reports and can occur even before clear neurologic diagnosis, so gallbladder health may be part of the overall MLD medical picture now and in the future, although the review cannot show how often problems happen in every clinic population. The inpatient study is not specific to MLD alone and does not explain exact causes of death, but it helps set expectations about what kinds of complications often accompany severe hospitalizations in leukodystrophies. Together, this month adds context that MLD care discussions may include both neurologic progression and non-neurologic complications, with some questions still open about who is most at risk and how best to predict problems early. [2] [3]